

**RESEARCH ARTICLE**

# Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Shambavi Richard<sup>1</sup>  | Ajai Chari<sup>1</sup> | Sosana Delimpasi<sup>2</sup> | Maryana Simonova<sup>3</sup> | Ivan Spicka<sup>4</sup> | Ludek Pour<sup>5</sup> | Iryna Kriachok<sup>6</sup> | Meletios A. Dimopoulos<sup>7</sup>  | Halyna Pylypenko<sup>8</sup> | Holger W. Auner<sup>9</sup>  | Xavier Leleu<sup>10</sup> | Ganna Usenko<sup>11</sup> | Roman Hajek<sup>12</sup> | Reuben Benjamin<sup>13</sup> | Tuphan Kanti Dolai<sup>14</sup> | Dinesh Kumar Sinha<sup>15</sup> | Christopher P. Venner<sup>16</sup> | Mamta Garg<sup>17</sup> | Don Ambrose Stevens<sup>18</sup> | Hang Quach<sup>19</sup> | Sundar Jagannath<sup>1</sup> | Phillipe Moreau<sup>20</sup>  | Moshe Levy<sup>21</sup> | Ashraf Badros<sup>22</sup> | Larry D. Anderson Jr<sup>23</sup> | Nizar J. Bahlis<sup>24</sup> | Thierry Facon<sup>25</sup> | Maria Victoria Mateos<sup>26</sup> | Michele Cavo<sup>27</sup> | Hua Chang<sup>28</sup> | Yosef Landesman<sup>28</sup> | Yi Chai<sup>28</sup> | Melina Arazy<sup>28</sup> | Jatin Shah<sup>28</sup> | Sharon Shacham<sup>28</sup> | Michael G. Kauffman<sup>28</sup> | Sebastian Grosicki<sup>29</sup> | Paul G. Richardson<sup>30</sup>

<sup>1</sup>Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, New York, USA

<sup>2</sup>General Hospital Evangelismos, Athens, Greece

<sup>3</sup>Institute of Blood Pathology & Transfusion Medicine of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine

<sup>4</sup>Charles University and General Hospital, Prague, Czech Republic

<sup>5</sup>Clinic of Internal Medicine —Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

<sup>6</sup>National Cancer Institute Ukraine, Kiev, Ukraine

<sup>7</sup>School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

<sup>8</sup>Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine

<sup>9</sup>Imperial College London, London, UK

<sup>10</sup>Department of Hematology, CHU la Miletie and Inserm CIC 1402, Poitiers, France

<sup>11</sup>City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine

<sup>12</sup>Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic

<sup>13</sup>Kings College Hospital NHS Foundation Trust, London, UK

<sup>14</sup>Nil Ratan Sircar Medical College and Hospital, Kolkata, India

<sup>15</sup>State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India

<sup>16</sup>Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

<sup>17</sup>University Hospitals of Leicester NHS Trust, Leicester, UK

<sup>18</sup>Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, USA

<sup>19</sup>University of Melbourne, St. Vincent's Hospital, Melbourne, Victoria, Australia

<sup>20</sup>University Hospital, Hotel-Dieu, Nantes, France

<sup>21</sup>Baylor University Medical Center, Dallas, Texas, USA

-----  
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *American Journal of Hematology* published by Wiley Periodicals LLC.

<sup>22</sup>University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA

<sup>23</sup>Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA

<sup>24</sup>University of Calgary, Charbonneau Cancer Research Institute, Calgary, Alberta, Canada

<sup>25</sup>CHU Lille Service des Maladies du Sang F-59000, Lille, France

<sup>26</sup>Hospital Universitario de Salamanca, Salamanca, Spain

<sup>27</sup>Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

<sup>28</sup>Karyopharm Therapeutics Inc., Newton, Massachusetts, USA

<sup>29</sup>Medical University of Silesia, Katowice, Poland

<sup>30</sup>Dana Farber Cancer Institute, Boston, Massachusetts, USA

#### Correspondence

Shambavi Richard, Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, New York, NY 10029, USA.

Email: shambavi.richard@mountsinai.org

#### Funding information

Karyopharm Therapeutics, Grant/Award

Number: N/A

#### Abstract

In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1–3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or  $\geq 4$  copies of amp1q21) cytogenetics (XVd,  $n = 70$ ; Vd,  $n = 71$ ), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd,  $n = 125$ ; Vd,  $n = 136$ ). Among patients with high-risk MM, median PFS was 12.91 months for XVd and 8.61 months for Vd (HR, 0.73 [95% CI, (0.4673, 1.1406)],  $p = 0.082$ ), and ORRs were 78.6% and 57.7%, respectively (OR 2.68;  $p = 0.004$ ). In the standard-risk subgroup, median PFS was 16.62 months for XVd and 9.46 months for Vd (HR 0.61;  $p = 0.004$ ), and ORRs were 75.2% and 64.7%, respectively (OR 1.65;  $p = 0.033$ ). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population. These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ClinicalTrials.gov identifier: NCT03110562.

## 1 | INTRODUCTION

Front-line treatment of multiple myeloma (MM) includes immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), and/or proteasome inhibitors (PI), with or without high dose alkylating agents followed by stem cell transplantation. Despite these highly active agents, essentially all patients will relapse and require subsequent therapies. Multiple myeloma cytogenetics have been shown to influence disease outcomes, with high-risk anomalies such as del(17p), t(4;14), t(14;16), and amp1q21<sup>1–3</sup> associated with shorter progression-free survival (PFS) and overall survival (OS) relative to those with standard-risk cytogenetics.<sup>4,5</sup> Given that patients with high-risk cytogenetics have inferior outcomes, there is a need to evaluate whether novel treatment regimens can overcome the negative impact of these cytogenetic alterations in patients with previously treated MM.

Exportin 1 (XPO1), an oncoprotein overexpressed in various hematologic and solid tumor malignancies including MM,<sup>6,7</sup> transports certain proteins and RNAs from the nucleus to the cytoplasm.<sup>8,9</sup> In

addition to correlating with more aggressive MM, elevated levels of XPO1 have been shown to correlate with resistance to proteasome inhibitors<sup>8–11</sup> and to IMiDs.<sup>12</sup> In cancer cells, overexpression of XPO1 leads to the nuclear export of tumor suppressor proteins (TSP) and the glucocorticoid receptor, culminating in their functional inactivation. High XPO1 also facilitates the nuclear export and translation of several oncoprotein mRNAs (e.g., cyclin D1, c-myc) leading to elevated oncoprotein levels.<sup>8,9,13</sup>

Selinexor is a potent, oral, selective inhibitor of nuclear export (SINE) compound that binds reversibly and selectively to Cys528 in the cargo-binding pocket of XPO1.<sup>14</sup> XPO1 inhibition forces the nuclear localization and functional inactivation of TSP, trapping I $\kappa$ B $\alpha$  in the nucleus leading to suppression of nuclear factor  $\kappa$ B (NF- $\kappa$ B) activity, enhanced glucocorticoid receptor function and reduction in oncoprotein mRNA translation.<sup>10,15</sup> These actions induce the apoptosis of tumor cells, while largely sparing normal cells.<sup>10,16</sup> In preclinical studies, selinexor increased p53 localization in the nucleus and synergized with PIs to induce significant cytotoxicity in PI-resistant MM

cells<sup>10</sup> and in a MM xenograft mouse model.<sup>17</sup> The phase 1b/2 STOMP study confirmed these data, with XVd demonstrating an ORR of 84% in patients with bortezomib non-refractory MM and 43% for patients with disease refractory to a PI in a previous line of therapy.<sup>18</sup> This was particularly compelling, as the XVd regimen utilized only once weekly bortezomib rather than the standard twice weekly bortezomib dosing, along with 25% less dexamethasone than standard Vd. Of note, two of the four patients with high-risk cytogenetics at screening responded to treatment with a CR in a patient with t(4;14) for 16.7 months and a VGPR in a patient with del(17p) for 32.9 months. Rates of peripheral neuropathy were low, consistent with the weekly bortezomib.

Selinexor is approved in the United States for the treatment of patients with previously treated MM<sup>19</sup> and diffuse large B-cell lymphoma.<sup>20</sup> The approval for MM was based on efficacy and safety in a prespecified subgroup analysis of 83 patients in Part 2 of the STORM study (NCT02336815), in which twice weekly sel-dex was administered to patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. The ORR was 25.3% with one stringent complete response (CR), four very good partial responses, and 16 partial responses.<sup>7</sup> In the phase 3 BOSTON study, treatment with the once weekly selinexor plus once weekly bortezomib and low dose (40 mg) dexamethasone (XVd) was compared with standard twice-weekly bortezomib and moderate dose (80 mg) dexamethasone (Vd) in patients with previously treated MM.<sup>19</sup> Overall, relative to Vd-treated patients, XVd-treated patients experienced significant improvements in median PFS (13.93 vs. 9.46 months; HR 0.70,  $p = 0.0075$ ) and ORR (76.4% vs. 62.3%), with lower rates of any-grade (32.3% vs. 47.1%) and grade  $\geq 2$  (21.0% vs. 34.3%) peripheral neuropathy,<sup>19</sup> with 37% fewer clinic visits required on the weekly XVd regimen. To further evaluate the impact of cytogenetics on the efficacy and safety of selinexor-based combination therapy, this report summarizes outcomes from pre-specified analyses of patients with high-risk versus standard-risk cytogenetics participating in the BOSTON study.

## 2 | PATIENTS AND METHODS

### 2.1 | Study design and patients

BOSTON (NCT03110562) was an international, active-controlled, open-label, randomized, phase 3 study.<sup>19</sup> Eligible patients were aged  $\geq 18$  years with histologically confirmed MM per International Myeloma Working Group (IMWG) criteria<sup>21</sup> previously treated with 1–3 anti-MM regimens. Prior treatment with a PI (alone or in combination) was permitted provided that the patient had achieved at least a partial response (PR), discontinuation was not due to a treatment-related grade  $\geq 3$  toxicity, and  $\geq 6$  months had elapsed since last dose. Patients with an Eastern Cooperative Oncology Group performance status score  $>2$ ; inadequate liver, renal, or hematopoietic function; active, unstable cardiovascular function; major surgery in the 4 weeks prior to the first dose of study treatment; a history of malignancy that required treatment or showed evidence of recurrence (PI refractory

disease was excluded); uncontrolled active infection; systemic light chain amyloidosis; MM characterized by central nervous system involvement; and  $>$ grade 2 peripheral neuropathy or grade  $\geq 2$  peripheral neuropathy with pain were ineligible.

BOSTON was conducted in compliance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, and applicable national and local regulatory requirements. The study protocol was approved by the Independent Ethics Committee/Institutional Review Board at each participating site, and all patients provided written informed consent.

### 2.2 | Treatment

Patients in each participating country were randomized (1:1) to either XVd or Vd, with randomization stratified by prior PI treatment (yes vs. no), number of prior anti-MM regimens (one vs. 2–3), and disease stage per the revised International Staging System (R-ISS; I–II vs. III). Those assigned to XVd received oral selinexor 100 mg on Days 1, 8, 15, 22, and 29; subcutaneous bortezomib 1.3 mg/m<sup>2</sup> on Days 1, 8, 15, and 22; and oral dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle. During cycles 1–8, patients assigned to Vd received subcutaneous bortezomib 1.3 mg/m<sup>2</sup> on Days 1, 4, 8, and 11 and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle. Beginning with cycle 9, patients assigned to Vd received bortezomib on Days 1, 8, 15, and 22 and dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle. Treatment was administered until disease progression, unacceptable toxicity, or another discontinuation criterion was met. Patients on the Vd arm who developed objective, IRC-confirmed progression were permitted to cross over to a selinexor-containing regimen.

### 2.3 | Outcomes

The primary endpoint was PFS (time from randomization to disease progression or death, whichever occurred first), as assessed by an independent review committee (IRC based on IMWG Criteria<sup>21</sup>). Secondary endpoints included OS (time from randomization to death or loss to follow-up), ORR (determined by IRC based on IMWG criteria), duration of response (DOR; time from first confirmed response [ $\geq$ PR] to confirmed disease progression or death, whichever occurred first), time to next therapy (TTNT; time from last dose of study treatment to first dose of non-study treatment), rates of grade  $\geq 2$  peripheral neuropathy and safety. Adverse events (AEs) were coded per the Medical Dictionary for Regulatory Activities version 22.0 and graded per Common Terminology Criteria for Adverse Events version 4.03.

In pre-specified analyses, the primary and secondary endpoints were evaluated in the subgroups of patients with high-risk and standard-risk cytogenetic features. Fluorescent in situ hybridization (FISH) was performed centrally on CD138-positive cells isolated from

bone marrow aspirates collected at screening. The high-risk group included patients with at least one of the following cytogenetic abnormalities: del(17p), t(4;14), t(14;16), or amplification ( $\geq 4$  copies) of 1q21 in at least 10% of screened plasma cells. Prognostic values of poor outcomes determined by FISH include cell positivity levels of 10%–20% for t(4;14) and t(14;16),<sup>22,23</sup> 50% for del(17p),<sup>24</sup> and 20% for amp1q21.<sup>24,25</sup> The standard-risk group consisted of all other patients with known or unknown baseline cytogenetics.

## 2.4 | Statistics

All efficacy analyses were performed on the intent-to-treat (ITT) population (all randomized patients). The safety population (all patients who received  $\geq 1$  dose of study treatment) was used for the safety analyses. PFS, OS, DOR, and TTNT were evaluated using the Kaplan–Meier method. The hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were estimated via

**TABLE 1** Baseline characteristics by cytogenetic risk status and treatment

	High-risk cytogenetics <sup>a</sup>		Standard-risk cytogenetics	
	XVd (n = 70)	Vd (n = 71)	XVd (n = 125)	Vd (n = 136)
Median age, years (range)	70 (45–84)	71 (49–90)	65 (40–87)	67 (38–84)
Age group, n (%)				
18–50 years	4 (5.7)	1 (1.4)	11 (8.8)	10 (7.4)
51–64 years	24 (34.3)	23 (32.4)	47 (37.6)	41 (30.1)
65–74 years	29 (41.4)	32 (45.1)	46 (36.8)	53 (39.0)
$\geq 75$ years	13 (18.6)	15 (21.1)	21 (16.8)	32 (23.5)
Male, n (%)	34 (48.6)	39 (54.9)	81 (64.8)	76 (55.9)
ECOG performance status, n (%)				
0	29 (41.4)	28 (39.4)	40 (32.0)	49 (36.0)
1	34 (48.6)	41 (57.7)	72 (57.6)	73 (53.7)
2	7 (10.0)	2 (2.8)	13 (10.4)	14 (10.3)
ISS stage at screening, n (%)				
I	37 (52.9)	34 (47.9)	60 (48.0)	68 (50.0)
II	21 (30.0)	26 (36.6)	45 (36.0)	47 (34.6)
III	12 (17.1)	11 (15.5)	20 (16.0)	21 (15.4)
R-ISS disease stage at screening, n (%)				
I	10 (14.3)	8 (11.3)	46 (36.8)	44 (32.4)
II	53 (75.7)	53 (74.6)	64 (51.2)	72 (52.9)
III	6 (8.6)	8 (11.3)	6 (4.8)	8 (5.9)
Unknown	1 (1.4)	2 (2.8)	9 (7.2)	12 (8.8)
Median time since initial diagnosis, years (range)	3.5 (1.1–23.0)	3.0 (0.6–22.0)	4.08 (0.4–21.5)	3.83 (0.4–18.4)
Lines of prior therapy, n (%)				
1	35 (50.0)	32 (45.1)	64 (51.2)	67 (49.3)
2	22 (31.4)	20 (28.2)	43 (34.4)	44 (32.4)
3	13 (18.6)	19 (26.8)	18 (14.4)	25 (18.4)
Prior SCT, n (%)	26 (37.1)	28 (39.4)	50 (40.0)	35 (25.7)
Prior therapy, n (%)				
Bortezomib	54 (77.1)	52 (73.2)	80 (64.0)	93 (68.4)
Carfilzomib	11 (15.7)	9 (12.7)	9 (7.2)	12 (8.8)
Ixazomib	3 (4.3)	1 (1.4)	3 (2.4)	2 (1.5)
Daratumumab	3 (4.3)	5 (7.0)	8 (6.4)	1 (0.7)
Lenalidomide	26 (37.1)	29 (40.8)	51 (40.8)	48 (35.3)
Pomalidomide	4 (5.7)	3 (4.2)	7 (5.6)	4 (2.9)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; R-ISS, Revised International Staging System; SCT, stem cell transplantation; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.


<sup>a</sup>Patients were considered high-risk if they presented with  $\geq 1$  of the following cytogenetic abnormalities: del17p, t(4;14), t(14;16), or amplification of 1q21 ( $\geq 4$  copies).

a Cox proportional-hazards model, with treatment as a covariate. Median survival/duration and associated 95% CIs were estimated via the Kaplan–Meier method. ORR was summarized using odds ratios (ORs) and 95% CIs. The differences between treatment arms in each cytogenetic risk subgroup were compared using either a one-sided, log-rank test (PFS, OS, DOR, and TTNT) or a one-sided, Cochran–Mantel–Haenszel chi-square test (ORR). Safety outcomes were summarized using descriptive statistics. As the BOSTON study was not powered for these pre-specified subgroup analyses, one-sided *p* values are used throughout and should be considered nominal (i.e., for illustrative purposes only).

### 3 | RESULTS

#### 3.1 | Patients

A total of 402 patients with MM previously treated with 1–3 prior regimens were randomized in the BOSTON study (XVd, *n* = 195; Vd, *n* = 207). Of these, 141 (35.1%) patients had MM with high-risk cytogenetics (XVd, *n* = 70; Vd, *n* = 71) and 261 (64.9%) had MM with standard-risk cytogenetics (XVd, *n* = 125; Vd, *n* = 136). Baseline demographic and disease characteristics were generally balanced between treatment arms in subgroups defined by cytogenetic risk



**FIGURE 1** Progression-free survival. Patients with A, high-risk and B, standard-risk cytogenetics. CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

(Table 1). In both treatment arms, amplification of 1q21 ( $\geq 4$  copies) was the most common cytogenetic abnormality (XVd, 22.1%; Vd, 18.8%) (Table S1). Proportionally fewer males than females had high-risk cytogenetic features (51.8% [73/141] vs. 60.2% [157/261]). Bortezomib was the most commonly used prior therapy (high-risk, 75.2% [106/141]; standard-risk, 66.3% [173/261]) followed by lenalidomide (high-risk, 39.0% [55/141]; standard-risk, 37.9% [99/261]).

### 3.2 | Efficacy

Median PFS in the high-risk group was longer for patients who received XVd (12.91 months) versus 8.61 months in those that received Vd (HR, 0.73; 95% CI, 0.47–1.14; one-sided  $p = 0.083$ ) (Figure 1(A)). Among those with standard-risk cytogenetics, median PFS

was longer for XVd than for Vd: 16.62 versus 9.46 months (HR, 0.61; 95% CI, 0.42–0.88; one-sided  $p = 0.004$ ) (Figure 1(B)).

The ORR was greater for XVd than for Vd in both the high-risk (78.6% vs. 57.7%; one-sided  $p = 0.004$ ) and standard-risk (75.2% vs. 64.7%;  $p = 0.033$ ) subgroups (Table 2). In the high-risk subgroup, the proportion of patients who achieved a very good PR (VGPR) or better was almost two-fold higher for XVd than for Vd (30.0% vs. 18.3%). Patients receiving XVd in both standard-risk and high-risk groups had had lower progressive disease (PD) rates than patients receiving Vd (high-risk, XVd 0% vs. Vd 7.0%; standard-risk, XVd 0.8% vs. Vd 3.7%). The rate of stable disease (SD) in high-risk patients was lower in the XVd arm (7.1%) as compared to the Vd arm (21.1%). Median TTNT was prolonged with XVd relative to Vd in both the high-risk (14.03 vs. 8.61 months; one-sided  $p = 0.018$ ) and standard-risk (18.23 vs. 11.73 months; one-sided  $p = 0.018$ ) subgroups (Table 2).

**TABLE 2** Efficacy outcomes by cytogenetic risk status and treatment

	High-risk cytogenetics <sup>a</sup>		Standard-risk cytogenetics	
	XVd (n = 70)	Vd (n = 71)	XVd (n = 125)	Vd (n = 136)
Median PFS	12.91	8.61	16.62	9.46
HR (95% CI)	0.73 (0.47–1.14)		0.61 (0.42–0.88)	
One-sided $p$ value	0.083		0.004	
Median OS, months	22.87	24.84	NR	NR
HR (95% CI)	0.87 (0.52–1.46)		0.75 (0.46–1.23)	
One-sided $p$ value	0.304		0.129	
ORR, n (%)	55 (78.6)	41 (57.7)	94 (75.2)	88 (64.7)
OR (95% CI)	2.68 (1.28–5.62)		1.65 (0.97–2.83)	
One-sided $p$ value	0.004		0.033	
Best overall response, n (%)				
Stringent CR	4 (5.7)	3 (4.2)	15 (12.0)	10 (7.4)
$\geq$ CR	4 (5.7)	5 (7.0)	10 (8.0)	4 (2.9)
VGPR	21 (30.0)	13 (18.3)	33 (26.4)	32 (23.5)
PR	26 (37.1)	20 (28.2)	36 (28.8)	42 (30.9)
MR	10 (14.3)	5 (7.0)	6 (4.8)	15 (11.0)
SD	5 (7.1)	15 (21.1)	20 (16.0)	25 (18.4)
PD	0	5 (7.0)	1 (0.8)	5 (3.7)
NE	0	5 (7.0)	4 (3.2)	3 (2.2)
Median DOR, months	12.55	12.68	NR	12.88
HR (95% CI)	1.04 (0.59–1.83)		0.61 (0.38–0.98)	
One-sided $p$ value	0.55		0.019	
Median TTNT, months	14.03	8.61	18.23	11.73
HR (95% CI)	0.64 (0.42–0.97)		0.71 (0.51–0.98)	
One-sided $p$ value	0.018		0.018	

Abbreviations: CI, confidence interval; CR, complete response; DOR, duration of response; HR, hazard ratio; MR, minimal response; NE, not evaluated; OR, odds ratio; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease; TTNT, time to next treatment; Vd, bortezomib and dexamethasone; VGPR, very good partial response; XVd, selinexor, bortezomib, and dexamethasone.

<sup>a</sup>Patients were considered high-risk if they presented with  $\geq 1$  of the following cytogenetic abnormalities: del17p, t(4;14), t(14;16), or amplification of 1q21 ( $\geq 4$  copies).

Despite patients in the trial being relatively early in their course of disease, the limited follow up (median around 21 months for all groups), and the ability for patients on Vd with objective progression to cross over to a selinexor containing regimen, the OS in the high- and standard-risk subgroups tended to favor XVd: In the high-risk subgroup, the HR for OS was 0.87 (XVd vs. Vd, 95% CI [0.52, 1.46], one-sided  $p = 0.304$ ). In the standard-risk subgroup, the HR for OS was 0.75 (95% CI [0.46, 1.23], one-sided  $p = 0.129$ ). Patients treated with XVd had numerically lower rates of death in both the standard

risk group (21.6%) and in the high-risk group (38.6%) as compared to Vd treated patients (28.7% and 43.7% respectively), although these trends did not reach statistical significance.

Efficacy endpoints were also evaluated by type of cytogenetic abnormality (Table S2). The results in patients with del(17p), that is, deletion of at least one copy of the p53 TSP, demonstrated a significant increase in PFS with XVd treatment (12.22 vs. 5.91 months; HR, 0.38; 95% CI, 0.16–086; one-sided  $p = 0.008$ ). ORR was significantly also improved with XVd compared to Vd: 76.2% vs. 37.5%

**TABLE 3** Safety outcomes by cytogenetic risk status and treatment

	High-risk cytogenetics <sup>a</sup>		Standard-risk cytogenetics	
	XVd (n = 70)	Vd (n = 70)	XVd (n = 125)	Vd (n = 134)
Any AE, n (%) <sup>b</sup>	70 (100.0)	66 (94.3)	124 (99.2)	132 (98.5)
Thrombocytopenia	50 (71.4)	23 (32.9)	70 (56.0)	33 (24.6)
Nausea	34 (48.6)	5 (7.1)	64 (51.2)	15 (11.2)
Fatigue	30 (42.9)	14 (20.0)	52 (41.6)	23 (17.2)
Neuropathy peripheral	26 (37.1)	34 (48.6)	37 (29.6)	63 (47.0)
Decreased appetite	22 (31.4)	1 (1.4)	47 (37.6)	10 (7.5)
Anemia	21 (30.0)	16 (22.9)	51 (40.8)	32 (23.9)
Diarrhea	20 (28.6)	14 (20.0)	45 (36.0)	38 (28.4)
Weight decreased	19 (27.1)	6 (8.6)	32 (25.6)	19 (14.2)
Asthenia	19 (27.1)	7 (10.0)	29 (23.2)	20 (14.9)
Upper respiratory tract infection	14 (20.0)	10 (14.3)	25 (20.0)	20 (14.9)
Cataract	11 (15.7)	5 (7.1)	32 (25.6)	9 (6.7)
Vomiting	11 (15.7)	0	29 (23.2)	10 (7.5)
Grade ≥3 hematologic AEs, n (%) <sup>c</sup>	60 (85.7)	45 (64.3)	106 (84.8)	82 (61.2)
Thrombocytopenia	38 (54.3)	14 (20.0)	40 (32.0)	22 (16.4)
Anemia	10 (14.3)	7 (10.0)	21 (16.8)	14 (10.4)
Neutropenia	9 (12.9)	5 (7.1)	8 (6.4)	2 (1.5)
Grade ≥3 non-hematologic AEs, n (%) <sup>c</sup>				
Pneumonia	11 (15.7)	9 (12.9)	11 (8.8)	13 (9.7)
Fatigue	10 (14.3)	0	16 (12.8)	2 (1.5)
Peripheral neuropathy	5 (7.1)	3 (4.3)	4 (3.2)	15 (11.2)
Asthenia	5 (7.1)	3 (4.3)	11 (8.8)	6 (4.5)
Cataract	6 (8.6)	1 (1.4)	13 (10.4)	3 (2.2)
Nausea	4 (5.7)	0	11 (8.8)	0
Hypertension	3 (4.3)	3 (4.3)	5 (4.0)	3 (2.2)
Diarrhea	2 (2.9)	0	11 (8.8)	1 (0.7)
Hypophosphatemia	3 (4.3)	1 (1.4)	7 (5.6)	2 (1.5)
Hyponatraemia	2 (2.9)	0	7 (5.6)	1 (0.7)
Vomiting	0	0	8 (6.4)	0
Decreased appetite	0	0	7 (5.6)	0
Discontinuation due to an AE, n (%)	11 (15.7)	6 (8.6)	30 (24.0)	26 (19.4)
Death due to an AE, n (%)	2 (2.9)	3 (4.3)	10 (8.0)	7 (5.2)

Abbreviations: AE, adverse event; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.

<sup>a</sup>Cytogenetic risk status was determined centrally via fluorescent in situ hybridization.

<sup>b</sup>Preferred terms reported in >20% of patients in any subgroup are presented.

<sup>c</sup>Preferred terms reported in >5% of patients in any subgroup are presented.



(OR 5.3, CI95% 1.28–22.19; one-sided  $p = 0.010$ ), as well as median TTNT: 14.78 versus 7.62 months (HR 0.30 95% CI, 0.12–0.75; one-sided  $p = 0.003$ ). Patients with del(17p) treated with XVd versus Vd had a trend towards improved DOR (14.75 vs. 6.82 months; HR 0.43, 95% CI 0.13–1.40; one-sided  $p = 0.08$ ). Interestingly, the OS in patients with del(17p) significantly favored XVd: HR 0.43 (95% CI 0.16–1.16; one-sided  $p = 0.04$ ), although the median values were similar: 22.21 versus 21.22 months. In the subset of patients with two or more cytogenetic abnormalities, a trend towards improved ORR was observed with XVd compared to Vd: 85.0% versus 64.7% (OR 3.09, 95% CI 0.64–15.00; one-sided  $p = 0.079$ ). While standard risk patients demonstrated significantly prolonged PFS with XVd, PFS in patients with  $\geq 2$  cytogenetic abnormalities receiving XVd (15.47 vs. 5.91 months; HR 0.54, 95% CI 0.22–1.33; one-sided  $p = 0.09$ ) and TTNT (14.03 vs. 7.62 months; HR 0.54, 95% CI 0.23–1.30; one-sided  $p = 0.082$ ) (Table S3) showed a trend in favor of XVd over Vd.

Generally, XVd conferred improvements in median PFS and ORR relative to Vd in patient subgroups defined by cytogenetic risk status except t(14;16) and baseline disease characteristics, including number of prior lines of therapy, prior treatment with lenalidomide, and creatinine clearance.<sup>19,26</sup> Interestingly, XVd was significantly more effective over Vd for patients with R-ISS Stages I-II disease (Table S4).

### 3.3 | Safety

In the high-risk and standard-risk subgroups, one and two patients, respectively, assigned to Vd did not receive study treatment. Thus, the safety analyses included 70 XVd-treated and 70 Vd-treated patients with high-risk cytogenetics and 125 XVd-treated and 134 Vd-treated patients with standard-risk cytogenetics. The safety profiles of XVd and Vd in the high-risk and standard-risk subgroups were generally similar. Over the course of the therapy (average duration e\_x007E;10 months), the majority of patients in each subgroup (94.3%–100.0%) experienced  $\geq 1$  AE (Table 3). In both cytogenetic risk subgroups, thrombocytopenia and nausea were the most common AEs and were more frequently reported in XVd- versus Vd-treated patients.

The most common grade  $\geq 3$  AE was thrombocytopenia, which was more common in XVd-treated than Vd-treated patients in both the high-risk (54.3% vs. 20.0%) and standard-risk (32.0% vs. 16.4%) subgroups (Table 3). Of note, despite the higher rates of thrombocytopenia with XVd versus Vd, the occurrence of clinically significant (Grade  $\geq 3$ ) bleeding was similar and low (i.e., only one in XVd and two in Vd). In the high-risk subgroup, the rate of grade  $\geq 2$  peripheral neuropathy was less common in XVd-treated than in Vd-treated patients (25.7% vs. 35.7%). Similarly, in the standard-risk subgroup, the rate of grade  $\geq 2$  peripheral neuropathy was lower with XVd than Vd (18.4% vs. 33.6%). The most common non-hematologic grade  $\geq 3$  AE was pneumonia, which occurred at similar frequencies across treatment arms in the high-risk (12.9%–15.7%) and standard-risk (9.7%–8.8%) subgroups.

The proportion of patients who discontinued treatment due to an AE was greater among XVd-treated than Vd-treated patients in the high-risk subgroup (15.7% vs. 8.6%) and in the standard-risk subgroup (24.0% vs. 19.4%). Five and 17 patients in the high-risk (XVd,  $n = 2$ ; Vd,  $n = 3$ ) and standard-risk (XVd,  $n = 10$ ; Vd,  $n = 7$ ) subgroups, respectively, died due to an AE.

## 4 | DISCUSSION

The BOSTON trial represents the first large Phase 3 study in previously treated MM to utilize once weekly bortezomib and low dose dexamethasone in the experimental arm, consistent with common clinical practice. The once weekly XVd regimen demonstrated superior PFS, ORR, and TTNT, with a trend towards improved OS, as compared with standard twice weekly Vd across the entire population of patients enrolled in the study. In the pre-specified subgroup analyses from the phase 3 BOSTON study, XVd yielded more favorable efficacy outcomes relative to Vd in patients with at least one prior MM therapy irrespective of cytogenetic risk status. These results become more striking when one considers that XVd-treated patients received 40% less bortezomib and 25% less dexamethasone, with  $\sim 37\%$  fewer clinic visits, than Vd-treated patients during the first 24 weeks of the study. Moreover, the use of weekly bortezomib in the XVd arm reflects the more common clinical practice when using bortezomib-based triplets. XVd treatment significantly improved PFS by 7 months compared to Vd in standard-risk patients, while a trend was observed in the high-risk subgroup, as XVd-treated patients tended to have longer median PFS duration compared to those receiving Vd. Despite the limitation of the cross-trial comparison, results compare favorably with subgroup analyses of two phase 3 studies of patients with previously treated MM: CASTOR and OPTIMISSM, both of which used higher doses of Vd on the experimental arms.

In CASTOR, patients were randomized to receive daratumumab (anti-CD38), twice weekly bortezomib, and moderate dose dexamethasone (DVD) or Vd,<sup>27</sup> but the bortezomib/dexamethasone was discontinued on both arms after 24 weeks. Among DVD-treated patients, the median PFS duration was 12.6 months in the high-risk subgroup and 16.6 months in the standard-risk subgroup.<sup>27</sup> Of note, the CASTOR subgroup analyses only regarded del(17p), t(4;14), and t(14;16) as high-risk cytogenetic abnormalities.<sup>27</sup> The present analysis of BOSTON also included amplification of 1q21, which is notable as the presence of  $\geq 3$  copies of 1q21 has been demonstrated to be negatively prognostic of response to bortezomib-based treatment and may confer resistance to bortezomib.<sup>28</sup> Here, we focused our analyses on the more conservative definition of  $\geq 4$  copies of 1q21 as high risk.<sup>29</sup> Of particular note, overall rates of PN on DVD were 49% and 55% in standard- and high-risk patients, respectively, substantially higher than the rates on the Vd arm in that study.<sup>27</sup>

In OPTIMISSM, patients with relapsed or refractory MM who had received 1–3 previous regimens (including two or more cycles of lenalidomide) and had progressive disease were randomly assigned 1:1 to pomalidomide, twice weekly bortezomib, and dexamethasone



(PvD) or Vd.<sup>30</sup> As in the CASTOR trial, patients were considered to be high risk if they had one of the following abnormalities: del(17p), t(4;14), or t(14;16). In this specified subgroup, median PFS was lower than that in the ITT population; however, patients receiving PvD had an improved PFS of 8.44 months as compared to 5.32 months in Vd-treated subjects (HR 0.56, 95% CI 0.35–0.90,  $p = 0.021$ ). In BOSTON, the PFS benefit observed in XVd-treated patients was most evident among those with del(17p), t(4;14), and amplification of 1q21 ( $\geq 4$  copies). Only the patients with t(14;16) trended more poorly on XVd versus Vd with a PFS HR of 1.46 and an overlapping 95% CI (0.45–4.80) with a one-sided  $p > 0.05$ . In contrast, the ORR in this subgroup was numerically higher (85%) in the XVd arm as compared to the Vd arm (55%). These disparate results may have been due to the small population of patients with t(14;16) MM in the study, and will be evaluated in future studies. In terms of ORR, deeper responses ( $\geq$ VGPR) were observed in XVd-treated versus Vd-treated patients with either high-risk (30.0% [21/70] vs. 18.3% [13/71]) or standard-risk (26.4% [33/125] vs. 23.5% [32/136]) cytogenetics. Moreover, the impact of XVd on efficacy outcomes did not appear to be negatively affected by the number of cytogenetic abnormalities or most baseline disease characteristics.

The safety profiles of XVd and Vd in the high-risk and standard-risk subgroups were similar to each other and consistent with those observed in the overall study population.<sup>19</sup> As in the primary analysis of BOSTON,<sup>19</sup> the most common grade  $\geq 3$  AE reported in the high-risk and standard-risk subgroups was thrombocytopenia. Importantly, rates of PN were lower in all XVd cohorts as compared with the Vd cohorts. While discontinuation rates were higher with XVd due to AEs, a significantly prolonged TTNT was observed suggesting that these patients were responding well and did not require immediate salvage therapy in contrast to patients who discontinued. Furthermore, improved supportive care as a result of physician experience is anticipated to further enhance the activity of XVd, and lead to a reduction in the number of patients discontinuing therapy due to AEs.

Preclinically, the combination of selinexor with a PI shows remarkable synergy.<sup>17,31,32</sup> Mechanistically, XPO1 inhibition forces the nuclear retention and functional activation of TSPs, and PIs prevent both the nuclear and cytoplasmic degradation of TSPs including I $\kappa$ B (and other proteins), leading to markedly higher levels of TSPs and reduced NF $\kappa$ B activity in the nucleus of cells treated with the combination as compared with the individual components.<sup>31,33</sup> With about 20 major TSPs, cells with abnormalities in one (e.g., del(17p) affecting p53 levels) or several of these proteins may be induced to undergo apoptosis via activation of remaining, wild type TSPs. Furthermore, the combination of selinexor with dexamethasone induces synergy on several levels: retention of transcriptionally active glucocorticoid receptor in the nucleus, induction of glucocorticoid anti-proliferative expression and activity leading to the inhibition of the mTOR pathway and to enhanced MM cancer cell death.<sup>32</sup>

Changes in gene expression that support cell proliferation and tumorigenesis have been observed in MM with any of the four high-risk cytogenetics analyzed in this study. Given the novel mechanism

of action against a single target that impacts most TSP pathways, we hypothesize that these high-risk associated changes would still be inhibited by selinexor. For example, del(17p) results in loss of the TSP p53 expression,<sup>34</sup> but the loss of p53 by (using siRNA knockdown) did not reduce sensitivity to selinexor.<sup>35</sup> Translocation of t(4;14) upregulates fibroblast growth factor receptor 3 (FGFR3),<sup>36</sup> which activates mitogenic pathways including AKT, MAP mTOR and NF $\kappa$ B – all inhibited by selinexor.<sup>37</sup> The t(4;14) and t(14;16) translocation may lead to the overexpression of the c-MAF protooncogene that upregulates IL-4 and IL-10 cytokine expression,<sup>38</sup> and selinexor may negate such transactivation through the inhibition of the NF $\kappa$ B signaling.<sup>39</sup> Lastly, the amp1q21 may result in the overexpression of CKS1B, upregulating cyclins and CDK activity, overcoming normal cell-cycle checkpoints that are activated by the inhibition of XPO1 with selinexor.<sup>37,40</sup> Taken together, despite the relatively small sample size for each cytogenetic abnormality, our results show significant differences based on high-risk cytogenetic profiles that also align with the potential mechanism of action.

BOSTON enrolled one of the greatest numbers of clinical trial participants with high-risk cytogenetics as compared to the other large bortezomib-based randomized studies.<sup>27,30</sup> However, even though the analyses in this subpopulation were pre-specified, a major limitation of the present analysis is the fact that BOSTON was not powered statistically to compare outcomes between patients with high-risk and standard-risk cytogenetics. While XVd improved outcomes compared to Vd in high-risk patients, the confidence intervals over suggest that standard-risk patients may have had more significant improvements. In addition, no adjustment was made for multiplicity testing, and the cytogenetic risk status was unknown for 10.0% of patients. Despite the plethora of additional therapies available to patients following progression on BOSTON, and allowing crossover from Vd to a selinexor-based regimen on objective progression, a trend towards improved OS for XVd over Vd was also observed, suggesting that treatment with selinexor may have modified the biology of the MM. However, given the limitations noted above, these results should be considered hypothesis-generating.

In conclusion, these data suggest that the oral XPO1 inhibitor selinexor, with its novel mechanism of action, can be used to treat patients with previously treated MM with either high-risk or standard-risk cytogenetics. XVd provided a non-IMiD-based regimen with superior benefits over Vd in a number of clinical outcomes across both the high-risk and standard-risk populations. Given that most patients now receive lenalidomide-based therapy in the frontline setting, a non-IMiD based, simple triplet regimen with reduced long-term toxicity (e.g., peripheral neuropathy) and without the need for intravenous or prolonged subcutaneous infusions makes it a viable option in the treatment of patients with MM after at least one prior regimen, whether they have high risk or standard risk disease.

## ACKNOWLEDGMENTS

This study was supported by research funding from Karyopharm Therapeutics, Inc. JetPub Scientific Communications LLC, supported by

Karyopharm Therapeutics, Inc., assisted in the preparation of this manuscript, in accordance with Good Publication Practice (GPP3) guidelines.

### CONFLICT OF INTEREST

Ajai Chari reports grants and personal fees from Janssen, Celgene, Novartis, Amgen, Seattle Genetics, and Millenium/Takeda; personal fees from Bristol Myers Squibb, Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, and Shattuch Labs.

Ivan Spicka reports personal fees from Janssen-Cilag, Takeda, Sanofi Aventis and Novartis; personal fees and non-financial support from Celgene, BMS and Amgen.

Iryna Kriachok reports a consulting role, an advisory role, and a speaker's bureau role for Takeda, Janssen, Roche, Abbvie and MSD; Travel support by Takeda, MSD, Roche, Abbvie and Janssen.

Holger W. Auner reports an advisory role for Takeda and Karyopharm; grant from Amgen; and a speaker's bureau role for Janssen.

Roman Hajek has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda.

Christopher P. Venner has received honoraria from BMS/Celgene, Janssen, Sanofi, Amgen, GSK, and Takeda.

Mamta Garg reports support for attending conferences from Takeda; an advisory role for Amgen, Takeda, Jansen, Novartis and Celgene; and a speaker's bureau role for Janssen.

Hang Quach reports grants from and an advisory board role for Amgen, Celgene, Karyopharm, GlaxoSmithKline; non-financial support and research drug supply from Sanofi; an advisory board role for Janssen Cilag and Specialized therapeutics.

Sundar Jagannath reports consulting services for AbbVie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck & Co. PM reports personal fees from Celgene, Amgen, Takeda, Janssen and Abbvie.

Moshe Levy reports receiving consulting fees and lecture fees from Takeda, Celgene, Seattle Genetics, AbbVie, Jazz Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Amgen, Spectrum Pharmaceuticals, and Janssen.

Larry D. Anderson, Jr. reports honoraria from advisory board activity from the following: GSK, Amgen, Janssen, BMS/Celgene, Karyopharm, and Oncopeptides.

Nizar J. Bahlis reports grants and personal fees from Celgene; personal fees from Janssen, Amgen, Takeda, Abbvie, GSK and Karyopharm.

Thierry Facon reports an advisory board role for Karyopharm, Amgen, Roche and Oncopeptides; an advisory board role and a speaker bureau role for Janssen, Celgene/BMS, and Takeda.

Maria Victoria Mateos has served as member of advisory boards or received honoraria from Janssen, BMS-Celgene, Takeda, Amgen, Sanofi, Oncopeptides, GSK, Adaptive, Pfizer, Regeneron, Roche and Sea-Gen.

Hua Chang, Yosef Landesman, Yi Chai, Melina Arazy, Jatin Shah and Michael G. Kauffman are salaried employees and stockholders of Karyopharm Therapeutics Inc.

Sharon Shacham reports being employed by and owning stock in Karyopharm Therapeutics, holding patents (8999996, 9079865, 9714226, PCT/US12/048319, and I574957) on hydrazide-containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 2012000928) on hydrazide-containing nuclear transport modulators and uses.

Paul G. Richardson reports receiving grant support and honoraria from Oncopeptides, Celgene, and Takeda, grant support from Bristol-Myers Squibb, and honoraria from Amgen, Janssen, and Karyopharm Therapeutics.

### DATA AVAILABILITY STATEMENT

Karyopharm Therapeutics agrees to share individual participant data that underlie the results reported in this article (after deidentification), including the study protocol and statistical analysis plan. Data availability will begin 9 months after publication and will be available 36 months after publication. To gain access, data requestors should submit a proposal to [medicalinformation@karyopharm.com](mailto:medicalinformation@karyopharm.com). Proposals will be reviewed by an independent review committee identified for this purpose.

### ORCID

Shambavi Richard  <https://orcid.org/0000-0003-0274-4292>

Meletios A. Dimopoulos  <https://orcid.org/0000-0001-8990-3254>

Holger W. Auner  <https://orcid.org/0000-0003-4040-0642>

Phillipe Moreau  <https://orcid.org/0000-0003-1780-8746>

### REFERENCES

- Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. *Blood*. 2006;108:1724-1732.
- Fonseca R, Bergsagel PL, Drach J, et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. *Leukemia*. 2009;23:2210-2221.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*. 2016;127:2955-2962.
- Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. *Leukemia*. 2018;32:102-110.
- Avet-Loiseau H, Durie BGM, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project. *Leukemia*. 2013;27:711-717.
- Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2018;18:335-380.
- Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*. 2019;381:727-738.
- Azizian NG, Li Y, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. *J Hematol Oncol*. 2020;13:1-9.
- Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. *J Hematol Oncol*. 2014;7:85. <https://doi.org/10.1186/s13045-014-0085-1>

10. Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. *Leukemia*. 2014;28:155-165.
11. Chanukuppa V, Paul D, Taunk K, et al. XPO1 is a critical player for bortezomib resistance in multiple myeloma: a quantitative proteomic approach. *J Proteomics*. 2019;209:103504.
12. Bhutani M, Zhang Q, Friend R, et al. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. *Lancet Haematol*. 2017;4:e443-e451.
13. Culjkovic-Kraljic B, Baguet A, Volpon L, Amri A, Borden KLB. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. *Cell Rep*. 2012;2:207-215.
14. Jardin F, Pujals A, Pelletier L, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. *Am J Hematol*. 2016;91:923-930.
15. Golomb L, Bublik DR, Wilder S, et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. *Mol Cell*. 2012;45:222-232.
16. Schmidt J, Braggio E, Kortuem KM, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. *Leukemia*. 2013;27:2357-2365.
17. Turner JG, Kashyap T, Dawson JL, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I $\kappa$ B $\alpha$  and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. *Oncotarget*. 2016;7:78896-78909.
18. Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. *Blood*. 2018;132:2546-2554.
19. Grosicki S, Simonova M, Picka I, et al. Once-weekly selinexor, bortezomib, and dexamethasone versus twice-weekly bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label phase 3 trial. *Lancet*. 2020;396:1563-1573.
20. XPOVIO<sup>®</sup> (selinexor), package insert. 2020. <http://www.fda.gov/medwatch>. Accessed February 1, 2021.
21. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. 2016;17:e328-e346.
22. Fonseca R, Oken MM, Greipp PR. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. *Blood*. 2001;98:1271-1272.
23. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma. *Cancer Research*. 2004;64:1546-1558.
24. An G, Li Z, Tai YT, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. *Clin Cancer Res*. 2015;21:2148-2156.
25. Hanamura I. Gain/amplification of chromosome arm 1q21 in multiple myeloma. *Cancers (Basel)*. 2021;13:1-16.
26. Mateos M, Gavriatopoulou M, Facon T, et al. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. *J Hematol Oncol*. 2021;14(1):1-5.
27. Weisel K, Spencer A, Lentzsch S, et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. *J Hematol Oncol*. 2020;13:115. <https://doi.org/10.1186/s13045-020-00948-5>
28. An G, Xu Y, Shi L, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. *Haematologica*. 2014;99:353-359.
29. Locher M, Steurer M, Jukic E, et al. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event. *Am J Hematol*. 2020;95:1562-1571.
30. Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20:781-794.
31. Kashyap T, Argueta C, Aboukameel A, et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF- $\kappa$ B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. *Oncotarget*. 2016;7:78883-78895.
32. Argueta C, Kashyap T, Klebanov B, et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. *Oncotarget*. 2018;9:25529-25544.
33. Turner JG, Dawson JL, Grant S, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. *J Hematol Oncol*. 2016;9:73.
34. Liu Y, Chen C, Xu Z, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. *Nature*. 2016;531:471-475.
35. Nakayama R, Zhang YX, Czaplinski JT, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. *Oncotarget*. 2016;7:16581-16592.
36. Kalf A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. *Blood Cancer J*. 2012;2:e89-e89.
37. Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. *Semin Cancer Biol*. 2014;27:74-86.
38. Cao S, Liu J, Song L, Ma X. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. *J Immunol*. 2005;174:3484-3492.
39. Wang AY, Liu H. The past, present, and future of CRM1/XPO1 inhibitors. *Stem Cell Investig*. 2019;6:6. <https://doi.org/10.21037/sci.2019.02.03>
40. Annunziata CM, Hernandez L, Davis RE, et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. *Blood*. 2011;117:2396-2404.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. *Am J Hematol*. 2021;96(9): 1120-1130. <https://doi.org/10.1002/ajh.26261>